![Meng Yuan Liu](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Meng Yuan Liu
Gründer bei Suzhou Kerui Gene Biotechnology Co., Ltd.
Profil
Meng Yuan Liu is the President & Director of Suzhou Kerui Gene Biotechnology Co., Ltd., which he founded in 2016.
Aktive Positionen von Meng Yuan Liu
Unternehmen | Position | Beginn |
---|---|---|
Suzhou Kerui Gene Biotechnology Co., Ltd.
![]() Suzhou Kerui Gene Biotechnology Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Suzhou Kerui Gene Biotechnology Co., Ltd., also known as Cure Genetics, is a biotech company founded in 2016 by Yuan Yuan Xu, Meng Yuan Liu, and Yanni Lin. The company is based in Suzhou, China. Cure Genetics is committed to expanding the frontier of gene therapy through its innovative technology of gene editing and gene delivery. With its world-leading AAV manufacturing capability, Cure Genetics' proprietary Velptm platform enables a fast yet systematic design, selection, and optimization of AAV vectors with special features and significantly better performance of in vivo gene delivery. The Chinese company aims to provide effective treatment options for patients worldwide with unmet medical needs and to establish itself as a benchmark in the field of cell and gene therapy. | Gründer | 13.07.2016 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Suzhou Kerui Gene Biotechnology Co., Ltd.
![]() Suzhou Kerui Gene Biotechnology Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Suzhou Kerui Gene Biotechnology Co., Ltd., also known as Cure Genetics, is a biotech company founded in 2016 by Yuan Yuan Xu, Meng Yuan Liu, and Yanni Lin. The company is based in Suzhou, China. Cure Genetics is committed to expanding the frontier of gene therapy through its innovative technology of gene editing and gene delivery. With its world-leading AAV manufacturing capability, Cure Genetics' proprietary Velptm platform enables a fast yet systematic design, selection, and optimization of AAV vectors with special features and significantly better performance of in vivo gene delivery. The Chinese company aims to provide effective treatment options for patients worldwide with unmet medical needs and to establish itself as a benchmark in the field of cell and gene therapy. | Commercial Services |